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Background Survival in mycosis fungoides (MF) is varied and may be poor. The
PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index)
study is a web-based data collection system for early-stage MF with legal data-
sharing agreements permitting international collaboration in a rare cancer with
complex pathology. Clinicopathological data must be 100% complete and in-built
intelligence in the database system ensures accurate staging.
Objectives To develop a prognostic index for MF.
Methods Predefined datasets for clinical, haematological, radiological, immunohis-
tochemical, genotypic, treatment and quality of life are collected at first diagnosis
of MF and annually to test against survival. Biobanked tissue samples are recorded
within a Federated Biobank for translational studies.
Results In total, 430 patients were enrolled from 29 centres in 15 countries span-
ning five continents. Altogether, 348 were confirmed as having early-stage MF at
central review. The majority had classical MF (816%) with a CD4 phenotype
(882%). Folliculotropic MF was diagnosed in 178%. Most presented with stage
I (IA: 494%; IB: 428%), but 78% presented with enlarged lymph nodes (stage
IIA). A diagnostic delay between first symptom development and initial diagnosis
was frequent [856%; median delay 36 months (interquartile range 12–90)].
This highlights the difficulties in accurate diagnosis, which includes lack of a sin-
gular diagnostic test for MF.
Conclusions This confirmed early-stage MF cohort is being followed-up to identify
prognostic factors, which may allow better management and improve survival by
identifying patients at risk of disease progression. This study design is a useful
model for collaboration in other rare diseases, especially where pathological diag-
nosis can be complex.
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What’s already known about this topic?
• Mycosis fungoides (MF) is a rare skin cancer that may closely mimic common
inflammatory dermatoses in early-stage disease.
• There is no singular diagnostic test for MF.
• Diagnosis of early-stage MF requires close clinical, pathological and genotypic cor-
relation.
What does this study add?
• This study reports on the clinical characteristics of a large international cohort of
patients with early-stage MF whose diagnosis has been confirmed following clini-
copathological review.
• The median age of presentation is 57 years, which is significantly younger than
those presenting with advanced-stage MF (66 years).
• This study confirmed a worldwide male predominance in early-stage MF (17
males : 1 female).
• A diagnostic delay is frequent (median 3 years).
Mycosis fungoides (MF) is a rare cancer, with an incidence of
< 1 per 100 000 but a much higher prevalence given the long
survival in early-stage disease (stages IA–IIA).1 Meaningful
studies in rare diseases require large-scale international collab-
orations to power them. Such collaboration requires expert
coordination, accessible data-collection systems and legal data-
share agreements to be implemented, which is challenging.
Here we present the PROCLIPI (PROspective International
Cutaneous Lymphoma Prognostic Index) study for early-stage
MF as a prototype study for international collaborations in rare
disease and present our initial findings and central review
process.
Diagnosis of early-stage MF (IA-IIA) is complex owing to a
number of factors, including varied clinical appearance and
similarity to inflammatory skin diseases such as eczema/psori-
asis, subtle variations in pathological/immunohistochemical
features and lack of a singular specific diagnostic test. Indeed,
interobserver variation for diagnosis of T-cell lymphomas,
including MF, is well recognized and a definite diagnosis often
requires careful clinicopathological correlation, with discor-
dance in diagnosis of ~20%.2 Hence, misdiagnosis and diag-
nostic delay are frequent. To confirm diagnosis in PROCLIPI,
all recruited patients were subject to expert central clinico-
pathological review. This is of paramount importance to
ensure patients meet criteria for a diagnosis of early-stage MF
and those with benign inflammatory dermatoses are rejected.
Patients with early-stage MF typically have a slowly progres-
sive evolution over years, or even decades, to widespread
patches or more infiltrated plaques. Morbidity can be consid-
erable, with pain, pruritus and disfigurement experienced, and
patients have been demonstrated to have a poor quality of
life.3,4 However, disease-specific mortality may occur in some
patients,5 and up to one-third of patients presenting with
early-stage disease progress within 10 years to advanced stage
disease (IIB–IVB),6 characterized by cutaneous tumours or ery-
throderma and/or nodal/leukemic/visceral involvement. If
patients with a poor prognosis could be preselected and
referred for more intensive management there may be
improved disease control and, potentially, survival. Given the
rarity of MF, only a large international multicentre prospective
study will improve our understanding and allow better diag-
nostic tests for more efficient diagnosis.
Specific clinical characteristics have been associated with a
worse prognosis in MF. However, most are associated with
advanced-stage disease and their relevance in early-stage disease
is unknown. These include male sex, higher age, raised serum lac-
tate dehydrogenase (LDH) and histological features, such as fol-
liculotropism and large-cell transformation (LCT).7–17 Some
favourable prognostic factors have been identified for early-stage
disease and include poikiloderma, hypopigmented patches, a
CD8+ phenotype and coexisting lymphomatoid papulosis.16,18–22
However, these studies are typically single-centre cohorts and
there is frequent discordance between reports. Benton et al. devel-
oped a cutaneous lymphoma prognostic index, but future publi-
cations could not validate this,10 and large international
collaborations are required to develop useful prospective indices.
An international prognostic index may select patients with early
MF at higher risk of disease progression for improved manage-
ment choices.
Patients and methods
Study design and patients
Datasets (Appendix S1; see Supporting Information) were
prospectively defined by the Cutaneous Lymphoma
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International Consortium over a series of meetings and tele-
conferences (2012–14). A secure web-based data system was
designed by University Hospital Birmingham (UHB) with in-
built intelligence to stage patients that does not allow data to
be saved unless clinicopathological datasets are complete. (This
database is housed on a secure UHB server, which is a secure
SQL Server housed behind Threat Management Gateway and
firewalls. The security of both the web application and techni-
cal infrastructure has been penetration-tested by an indepen-
dent ethical hack/security company.) Selected fields are
duplicated to cross-check for data consistency. No patient-
identifiable data are shared and patients are anonymised
centrally.
Specialist international centres treating MF were selected via
membership to expert international groups (European Organi-
zation for Research and Treatment of Cancer, International
Society for Cutaneous Lymphoma). A data-sharing agreement
was signed between each participating centre and UHB. (On
most occasions the generic agreement was signed, but owing
to the complexity of data sharing and different stipulations
between countries, if required, minor amendments were
made.)
Since July 2015, all patients referred to the participating
centres with a new diagnosis of early-stage MF within the
prior 6 months were eligible. The study was reviewed and
approved by local ethical committees/institutional review
boards prior to recruitment. Patients were given verbal and
written patient information about PROCLIPI in their native
language. Written consent for participation in this study, anal-
ysis of data and use of blood, skin and lymph tissue for future
translational research (Federated Biobank) was obtained at trial
entry.
For each recruited patient data on clinical, haematological,
pathological, lymph nodes (LN), viscera, bone marrow, geno-
typical, treatment and quality-of-life information [recorded
using the U.S.A. Skindex-29 questionnaire (permission granted
by MAPI Research Trust, Lyon, France) with translations into
English, Spanish, German, Dutch and Italian)] (Appendix S1;
see Supporting Information) is collected at time of diagnosis
and updated annually or earlier in the event of disease stage
progression or death (Appendix S2; see Supporting Informa-
tion). The time in months from onset of MF lesions (as
reported by the patient) and first diagnosis of MF at their cen-
tre was recorded to investigate any delay in diagnosis. Delay
in diagnosis includes both failure of patients to present to
physicians and physicians’ delay, and was predefined as the
time from occurrence of the patient’s first skin lesions and a
clinicopathological diagnosis made by their clinician. This
time did not include time to central pathology review.
Data monitoring
The PROCLIPI database has an in-built intelligence system that
creates e-mail alerts for missing or overdue data, disallows sav-
ing of numerically impossible/highly unlikely data, prevents
saving of incomplete data and auto-calculates modified severity-
weighted assessment tool (mSWAT), which reflects skin tumour
burden and provides a numerical value between 0 and 400,23,24
blood classification and overall stage (using TNMB).25 Addition-
ally, a Data Monitoring Committee (Appendix S3; see Support-
ing Information) manually reviews data for inaccuracies.
Queries are raised to the respective institutions if data inaccura-
cies are suspected and for missed updates.
Central review
All patients were subject to a clinicopathological review prior
to the patient’s data being included in the analysis. This was
performed to confirm early-stage MF and prevent inclusion of
patients with either reactive skin changes or advanced MF.
Three internationally recognized leading dermatologists and
dermatopathology specialists formed the central review panel
(R.W., L.C., W.K.). The diagnosis of early-stage MF was based
on a combination of clinical, histopathological and
immunophenotypical criteria, as published previously.2 An
initial virtual review of representative clinical photographs of
cutaneous lesions together with photomicrographs of haema-
toxylin and eosin, CD3, CD4 and CD8 stains was performed.
In unclear cases, slides were requested to have a real-time cen-
tral review. Details of the review processes are described in
Appendix S4 (see Supporting Information).
Statistical analysis
The Kruskal–Wallis test was used to analyse difference in
medians for the nonparametric continuous variables. The
X2-test was used to determine differences in categorical vari-
ables. Nonparametric continuous variables are presented as
medians and interquartile ranges (IQR). Analyses were per-




Twenty-nine international centres enrolled 430 patients
(Fig. 1). Centres unable to comply with the central review
process were not eligible for inclusion. Virtual central review
confirmed 329 patients as having early-stage MF. Sixty-four
were referred for a real-time central review and 37 failed (13
advanced-stage MF and 24 nondiagnostic of MF). Real-time
review was possible for 41 of 64 patients (641%), with 19
of 41 (463%) passing. At the time of writing, 23 are await-
ing real-time review; thus, 407 of 430 patients (946%) have
completed central review; 348 of 407 patients (855%) were
confirmed as having early-stage MF, 16 of 407 (39%) had
advanced-stage disease and 43 of 407 (105%) were diagnos-
tic of MF (106%) (Fig. 2).
This report focuses on the 348 patients passing the central
review process. However, all patients entered into the PRO-
CLIPI database are followed-up as it is appreciated some of
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these patients may develop MF or have true MF, which could
not be confirmed by the central review process. In reality, all
these patients may be receiving MF treatment at their local
centre.
Patient demographics
Of the 348 patients, there was a male predominance [219
males, 129 females (ratio 17 : 1)]. Table 1 shows the clinical
characteristics of the patients.
In total, 172 patients (494%) had clinical stage IA MF, 149
(428%) had stage IB MF and 27 (78%) had stage IIA MF.
Median age at diagnosis was 57 years (IQR 44–67), without
significant differences between stage IA (median age 54 years;
IQR 44–66), stage IB (median age 57 years; IQR 45–67) and
stage IIA [median age 61 years; IQR 44–73 (P = 0285)]. In
total, 298 patients (856%) reported a diagnostic delay, with a
median delay of 36 months (IQR 129). This was similar for
all stages (P = 0141): 36 months (IQR 12–72) for stage IA;
48 months (IQR 24–100) for stage IB; and 33 months (IQR
Fig 1. PROCLIPI (PROspective International Cutaneous Lymphoma Prognostic Index) recruitment plus central review results per centre.
Enrolled for central 
review 




Rejected  (n = 37)
Non-
diagnostic Advanced stage
(n = 13)(n = 24)
Early stage MF 
(n = 19)






Early stage MF 
(n = 348)




Still awaits real-time 
review 
(n = 23)
Fig 2. Central review process and results.
© 2018 British Association of Dermatologists British Journal of Dermatology (2019) 181, pp350–357
PROCLIPI study investigating prognostic factors in early-stage MF, J.J. Scarisbrick et al. 353
15–87) for stage IIA. Eastern Cooperative Oncology Group
(ECOG) scores were 0 in 338 patients, 1 in eight patients, 2
in one patient and 4 in one patient.
The median mSWAT score at diagnosis of stage IA was 5
(IQR 2–8), 26 (IQR 17–45) for stage IB and 322 (IQR 11–
70) for IIA. The clinical phenotype was patch-only lesions in
160 patients (460%), significantly more often in stage IA/B
(535% and 423%, respectively) than IIA (185%; P =
0002). Fifty-two patients (149%) had plaque-only lesions,
31 of 172 (180%) with stage IA MF, 18 of 149 (121%)
with IB MF and three of 27 (111%) with IIA MF. The
remaining 136 patients (391%) had coexisting patches and
plaques. Other clinical features recorded included follicular
lesions (244%), poikiloderma (152%) and hypopigmented
lesions (80%).
Follicular lesions (clinical lesions of MF showing predilec-
tion for hair follicles and include follicular papules, plaques,
alopecia, milia and cysts) were present in 85 patients; 67
received a diagnosis of folliculotropic MF (FMF), but follicular
lesions also occur in classical MF. Follicular lesions were less
common in patients with IA MF (144%) than type IB
(322%) or IIA (260%) MF (P = 0009). While poikiloderma
and hypopigmentation were found at a similar frequency in
all stages (P = 0452 and P = 0313, respectively), there was a
positive association with patches. Twelve (34%) patients had
coexisting lymphomatoid papulosis lesions, which is similar to
what has previously been reported.15,16
Skin histology and clonality
From central pathology review, 284 patients had classical MF
(816%), 62 (178%) had FMF and two syringotropic MF
(06%). The T-cell phenotype was CD4+ in 307 patients
(882%). In the 41 with negatively staining CD4 tumour cells,
34 were CD4–CD8–. In addition to CD4 positivity, seven also
had tumour cells that stained CD4+CD8+. Six patients (17%)
had LCT in the skin, two of whom had FMF.
Not all sites perform T-cell receptor (TCR) gene analysis in
the skin. This was recorded in 205 patients and was clonal in
132 patients (644%) at a similar percentage in all stages (P =
0848); 70 of 109 (642%) with stage IA MF, 46 of 73
(630%) with stage IB MF and 16 of 23 (696%) with stage
IIA MF.
Haematological parameters and serum lactate
dehydrogenase
B-classification data were available in 121 of 348 patients and
was B0 in 96 of 121 patients (793%) and B1 in 25 of 121
patients (207%; Table 2). By staging definition, no patients
had B2, which is a criterion for advanced-stage disease (≥
IVA1). Of the 25 patients with B1, 10 of 55 (182%) had
stage IA MF, 12 of 46 (261%) had stage IB MF and three of
21 (143%) stage IIA MF. Only 336% had TCR in blood
tested and this was clonal in 85% (n = 10). Full blood count
and differential was tested in 687%. Lymphopenia was a fre-
quent abnormality found in 103%; 17% had lymphocytosis.
LDH was recorded in 244 of 348 patients (701%) and was
raised in 27 patients (111%), particularly in stage IIA (n =
10/23; 435%) with respect to stage IA (n = 8/120; 67%)
and stage IB MF (n = 9/101; 89%) (P < 0001).
Lymph node involvement
Radiological imaging was not mandatory for this study. It was
performed in 143 patients (411%); 23 of 143 patients
(161%) had LN enlargement by computed tomography crite-
ria for MF, defined as ≥ 15 mm in the greatest diameter (long
Table 1 Clinical data of 348 patients with early-stage mycosis fungoides (MF)
Stage IA Stage IB Stage IIA All
Patients (n) 172 149 27 348
Median (IQR) age (years) 54 (44–66) 57 (45–67) 61 (44–73) 57 (44–67)
Female 64 (372) 58 (389) 7 (259) 129 (371)
Male 108 (628) 91 (611) 20 (741) 219 (629)
Classical MF 140 (814) 112 (752) 22 (815) 274 (787)
Folliculotropic MF 28 (163) 37 (248) 5 (185) 70 (201)
Clinical alopecia 13 (76) 27 (181) 9 (333) 49 (141)
Follicular skin lesions 30 (174) 48 (322) 7 (259) 85 (244)
Poikiloderma 22 (128) 26 (174) 5 (185) 53 (152)
Hypopigmentation 10 (58) 15 (101) 3 (111) 28 (80)
Confluent erythema 4 (23) 17 (114) 6 (222) 27 (78)
Median (IQR) mSWAT patch 3 (1–5) 15 (10–25) 10 (3–398) 6 (2–15)
Median (IQR) mSWAT plaque 0 (0–2) 2 (0–11) 6 (1–12) 09 (0–5)
Median (IQR) mSWAT tumour 0 0 0 0
Median (IQR) mSWAT score 5 (2–8) 26 (17–45) 322 (11–70) 11 (5–28)
Duration of MF-like lesions (months) 36 (12–72) 48 (24–100) 33 (15–87) 36 (12–90)
Data are n (%) unless otherwise indicated. IQR, interquartile range; mSWAT, modified severity-weighted assessment tool.
© 2018 British Association of DermatologistsBritish Journal of Dermatology (2019) 181, pp350–357
354 PROCLIPI study investigating prognostic factors in early-stage MF, J.J. Scarisbrick et al.
axis). By staging definition, these patients have stage IIA MF.
No patients had visceral disease, which would be an advanced
stage (IVB).
Of the 23 patients with enlarged LN on imaging, nine had
enlarged nodes at one region, whereas the remaining had ≥ 2
(five at two regions, four at three regions, four at four regions
and one at more than five regions). Lymphadenopathy was
mostly found at peripheral sites (695% inguinofemoral,
565% axillary and 217% cervical). Only one patient had cen-
trally enlarged LN (one abdominal). Six patients had an LN
biopsy: four were classed as N1 (dermatopathic lym-
phadenopathy) and two as N2 (early nodal involvement).25
The remaining 21 patients with stage IIA MF were recorded as
Nx (four with LN identified by clinical exam alone, no imag-
ing/biopsy and 17 with LN identified on imaging without
biopsy).
Discussion
PROCLIPI is a prototype data collection study for rare cancers.
The PROCLIPI database is an easily accessible secure web-
based system with predefined datasets to allow prospective
collection of international data. This unique database checks
the accuracy of information using in-built intelligence, which
auto-calculates stage, prevents entry of obscure data and disal-
lows saving of incomplete data. In addition, once a year a
Data Monitoring Committee (Appendix S1; see Supporting
Information) trawls data for inaccuracies, which are then
raised as queries to centres. Legal data-sharing agreements
allow anonymized international data share. An associated
Federated Biobank registers tissue stored for future transla-
tional studies, providing an invaluable resource of detailed
clinicopathological/genotypic data linked to pretreatment bio-
banked samples.
In 3 years, PROCLIPI recruited a cohort of 430 patients sus-
pected as having early-stage MF from 29 centres in 15 coun-
tries spanning five continents. This unprecedented
collaboration will test parameters recorded against survival to
develop a prognostic index powered to identify patients with
early-stage MF at higher risk of disease progression.
Diagnosis of early-stage MF is complex.2 Hence, all enrolled
patients are subject to a rigorous clinicopathological review.
Overall, the central review process was concordant with the
diagnosis of early-stage MF in 855% of patients, with most
‘passing’ on the initial ‘virtual central review’ process. Forty-
one patients had real-time review and the ‘pass rate’ was
463%. Failure of central review was due to advanced-stage
disease (39%) and nondiagnosis (106%). Interestingly,
despite the strict criteria for passing central review, of those
tested for T-cell clonality in skin (performed at individual sites
not centrally), only 644% had identification of a T-cell skin
clone with similar frequency at each stage (P = 0848).
Methodology most frequently included the Biomed 2 panel,26
with only one centre using high-throughput sequencing
(HTS) platforms.27 The sensitivity of standard polymerase
chain reaction (and subjective reading by gel electrophoresis)
is less than clinically used HTS platforms.28 Results cannot be
standardized given the heterogeneity of methods used region-
ally/locally. Thus, clonality alone is not a reliable sensitive
diagnostic test.
Table 2 Haematological data from 348 patients with early-stage mycosis fungoides
Stage IA Stage IB Stage IIA All
Patients (n) 172 149 27 348
B classification
B0a 45 (818) 34 (739) 17 (850) 96 (793)
B1a 10 (182) 12 (261) 3 (150) 25 (207)
B2a 0 0 0 0
Bx 117 (680) 103 (691) 7 (259) 227 (652)
Raised ALC 2 (12) 3 (20) 1 (37) 6 (17)
Low ALC 9 (52) 19 (128) 8 (296) 36 (103)
Missing ALC 54 (314) 52 (349) 3 (111) 109 (313)
Raised LDH 8 (47) 9 (60) 10 (370) 27 (78)
Missing LDH 52 (302) 48 (322) 4 (148) 104 (299)
Raised WCC 6 (35) 13 (87) 5 (185) 24 (69)
Low WCC 4 (23) 4 (27) 2 (74) 10 (29)
Missing WCC 44 (256) 46 (309) 2 (74) 92 (264)
Median (IQR) % lymphocytes 301 (250–351) 272 (212–313) 212 (160–293) 281 (217–334)
Clonality skin test performed 109 (634) 73 (490) 25 (926) 207 (595)
Clonality blood test performed 51 (297) 51 (342) 15 (556) 117 (336)
Clonal identical to indexb 5 (98) 2 (39) 3 (200) 10 (85)
Clonal nonidentical to indexb 6 (118) 7 (137) 1 (67) 14 (120)
Data are n (%) unless otherwise indicated. ALC, absolute lymphocyte count; LDH, lactate dehydrogenase; WCC, white cell count; IQR,
interquartile range. aDenominator excludes those classified Bx, i.e. insufficient data to score as B class. bDenominator only includes those who
had a clonality blood test performed.
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In 856% of patients, there was a diagnostic delay (median
36 months, not including time for central review) from onset
of lesions to diagnosis of early MF in participating centres,
highlighting the need for improved diagnostic tests in early-
stage MF. Most patients presented with stage I (494% stage
IA, 428% stage IB), but 78% presented with nodal enlarge-
ment (stage IIA). No difference in delay was noted between
stages, suggesting that stages IB–IIA are not late diagnoses of
patients with stage ‘IA’ MF. It could be interpreted that a delay
does not result in progression of skin involvement (to a
higher stage at least). Nonetheless, delay can be stressful for
patients and has the potential to lead to inappropriate treat-
ments. Indeed, at worst, misdiagnosis, particularly when fol-
lowed by inappropriate use of immunosuppressive therapy,
may result in a more rapid disease progression.29
Most (816%) presented with classical MF and 178% with
FMF, ratified at central review. FMF has previously been associ-
ated with more aggressive disease and a prognosis more similar
to tumour-stage disease.7 However, recent publications have
shown a subgroup of patients with FMF with early-stage disease
with a good prognosis;30–32 these patients will be tracked to
determine the prognostic relevance of FMF in early-stage MF.
Distinguishing patches from plaques of MF is subjective but
may determine treatment approaches in early-stage dis-
ease.33,34 Benton et al. found the presence of plaques to be an
independent factor for poor survival in early-stage disease,10
but an adverse outcome due to plaque lesions at diagnosis has
not been shown in a prospective study. The revised 2007 stag-
ing guidelines do not include plaques as a determinant of
stage but recommended recording the presence of patch only
or patches/plaques (‘a’ for patches and ‘b’ for patches/pla-
ques). In total, 460% of our cohort presented with patch-
only disease and 391% with patches/plaques. Plaques were
seen in 465% with stage IA MF but were more frequent in IB
disease (577%; P = 0045).
The majority of patients (971%) presented in good health,
with an ECOG score of 0. There was a male predominance
with male : female ratio of 17 : 1; median age of presenta-
tion was 57 years (IQR 44–67), with no difference between
stages. This is significantly younger than the median age of
645 years (IQR 55–74) of the cohort of 1275 patients with
advanced-stage MF reported by our group (P < 0001).15 This
retrospective analysis of advanced-stage MF found age > 60
years, LCT in skin, stage IV and raised LDH all to be indepen-
dent factors with a worse prognosis,12 but the significance of
these findings in early-stage MF is unknown. In this early
cohort LCT was verified at central review in 17% of cases. A
raised serum LDH was found in 111% and was significantly
raised in stage IIA MF (435%) compared with stage IA
(67%) and IB (89%) MF (P < 0001).
Blood involvement in early-stage MF is part of the staging
for MF and is utilized in the response criteria.35,36 The major-
ity of patients tested had no blood involvement (B0 = 793%)
but B1-level blood involvement was found in 207%, occur-
ring in all stages. Lymphopenia was a frequent haematological
abnormality in this cohort with early-stage MF (103%) and
increased to 296% in stage IIA disease. It should be noted
these tests are carried out at diagnosis, so MF treatment is not
the cause. Lymphopenia is associated with immunosuppres-
sion, which may reduce the innate immunity ability to keep
cancers – or specifically MF – in check. Ciclosporin, a potent
suppressor of lymphocytes, is known to precipitate more
aggressive MF and is contraindicated.6,29 The significance of
blood abnormalities in early-stage MF is unknown and track-
ing these patients for survival will determine the relevance.
Radiological imaging is not a recommended investigation in
early-stage MF unless there is clinical lymphadenopathy or
type-B symptoms, but nearly half of patients had an imaging
scan (n = 143; 411%), although only 23 of 143 patients
(161%) had enlarged LN.
PROCLIPI has collected a confirmed early-stage MF cohort
that will be followed-up for survival to identify prognostic
factors that may allow better management and improve sur-
vival by identifying patients at risk of MF progression. There
is frequent diagnostic delay (median 36 months), highlighting
the difficulties in accurate diagnosis, which is confounded by
the lack of a singular diagnostic test and currently relies on
clinical, pathological and genotypic studies. Tissue samples
within the PROCLIPI federated biobank may be used for future
translational studies, which may identify biomarkers to aid
diagnosis and to identify predictive and prognostic biomarkers
and novel targets for therapy. This study design is a prototype
that may be useful in other rare diseases.
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